NTBL.Q Stock Overview
A clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Notable Labs, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.16 |
| 52 Week High | US$4.24 |
| 52 Week Low | US$0.10 |
| Beta | 0 |
| 11 Month Change | -62.79% |
| 3 Month Change | -70.36% |
| 1 Year Change | -93.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| NTBL.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -27.2% | 0.5% | 0.5% |
| 1Y | -93.7% | 24.7% | 36.8% |
Return vs Industry: NTBL.Q underperformed the US Biotechs industry which returned 27% over the past year.
Return vs Market: NTBL.Q underperformed the US Market which returned 38.6% over the past year.
Price Volatility
| NTBL.Q volatility | |
|---|---|
| NTBL.Q Average Weekly Movement | 23.9% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTBL.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NTBL.Q's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 16 | Kaile Zagger | www.notablelabs.com |
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population.
Notable Labs, Ltd. Fundamentals Summary
| NTBL.Q fundamental statistics | |
|---|---|
| Market cap | US$1.45m |
| Earnings (TTM) | -US$10.54m |
| Revenue (TTM) | US$313.00k |
4.9x
P/S Ratio-0.1x
P/E RatioIs NTBL.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTBL.Q income statement (TTM) | |
|---|---|
| Revenue | US$313.00k |
| Cost of Revenue | US$197.00k |
| Gross Profit | US$116.00k |
| Other Expenses | US$10.66m |
| Earnings | -US$10.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 37.06% |
| Net Profit Margin | -3,368.05% |
| Debt/Equity Ratio | 0% |
How did NTBL.Q perform over the long term?
See historical performance and comparison